Novellus Systems today introduced the SABRE Excel, an advanced copper electroplating system designed to provide industry-leading fill and defect density performance for the 22nm technology node and beyond.
NanoSight, manufacturers of unique nanoparticle characterisation technology, has announced that the Centre for Molecular Nanometrology at the University of Strathclyde has selected an LM-10 characterisation system to aid in their research and development of new biosensors.
Applied Nanotech Holdings, Inc. announced that it has entered into a strategic agreement with UniJet Co. Ltd, an original equipment manufacturer of industrial scale inkjet printing systems for high volume manufacturing and a global leader in the emerging field of printed electronics.
Nikon Instruments, Inc. has unveiled its new A1R MP Multiphoton and Confocal microscope system for high speed, high resolution and high sensitivity multiphoton excitation and confocal fluorescence imaging.
The specialist product development consultancy, Bio Nano Consulting (BNC) is pleased to announce that it has been chosen to lead the UK arm of a collaboration with a major research institution in the Middle East in a multi-million pound environmental nanotechnology endeavour.
Semiconductor Manufacturing International Corporation has adopted Cadenc Litho Physical Analyzer and Cadence Litho Electrical Analyzer to more accurately predict the impact of stress and lithographic variability on the performance of 65- and 45-nanometer semiconductor designs.
The VivaTome for fluorescence microscopes from Carl Zeiss is an optimal tool for developmental and cell biologists to examine the dynamics of living specimens without extensive prior know- ledge of optical sectioning.
With the LSM 780, Carl Zeiss is now adding a new member to its family of LSM 7 laser scanning microscopes. The use of the new GaAsP detector technology has almost doubled the sensitivity of the currently leading LSM 710.
Cancer Therapeutics, Inc., an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies.
Contributing to the poster presentations at the 2009 AAPS Annual Meeting and Exposition (8-12 November 2009: Los Angeles, USA), researchers from Solvay Pharmaceuticals Inc and Malvern Instruments will present details of a study to examine particle size, shape and distribution data for equivalency testing of a highly cohesive drug substance manufactured at two different sites.